Treating immune-mediated diseases with nanoparticles
In this Q&A, we had the privilege of speaking to…
In this Q&A, we had the privilege of speaking to COUR Pharmaceuticals’ CEO John Puisis. He offers insights into how their innovative immune-modifying nanoparticle platform differs from traditional approaches for treating immune-mediated diseases.